Original Research

An Open-Label, Multicenter Study of the Efficacy and Safety of an AM/PM Treatment Regimen With Clobetasol Propionate Spray 0.05% and Calcitriol Ointment 3 μg/g in the Management of Plaque Psoriasis

Author and Disclosure Information

Psoriasis is a chronic condition with serious quality-of-life ramifications. Dermatologists seek alternative treatments of patients with plaque psoriasis that provide both efficacy and safety while minimizing exposure to high-potency steroids that can have adverse effects following long-term use. We report an open-label, multicenter study designed to evaluate a morning/evening (AM/PM) treatment regimen involving clobetasol propionate spray 0.05% and calcitriol ointment 3 μg/g for moderate plaque psoriasis. Participants applied clobetasol propionate spray 0.05% in the morning and calcitriol ointment 3 μg/g in the evening for up to 4 weeks. Participants were evaluated at baseline, week 2, and week 4. The results of this study indicate that a 4-week regimen of clobetasol propionate spray 0.05% treatment in the morning and calcitriol ointment 3 μg/g in the evening is efficacious and without unexpected safety issues for the management of moderate plaque psoriasis.


 

Recommended Reading

Off-Label Uses for Biologics Growing
MDedge Dermatology
DANBIO: Anti-TNFs Do Not Up Overall Cancer Risk
MDedge Dermatology
Clobex Followed by Vectical Wallops Psoriasis
MDedge Dermatology
Patient Subgroup Response to Belimumab Remains Unclear
MDedge Dermatology
Bosentan May Reduce Skin Fibrosis in Scleroderma
MDedge Dermatology
Rituximab Deemed Useful for Certain Lupus Subgroups
MDedge Dermatology
308-nm Excimer Laser Effective for Treating Palmoplantar Psoriasis
MDedge Dermatology
Biologics Don't Increase Herpes Zoster Risk
MDedge Dermatology
DMARDs for Psoriasis May Cut Diabetes Risk
MDedge Dermatology
Topical Combo Shows Early Promise in Moderate Psoriasis
MDedge Dermatology